Ocular adnexal lymphoma (OAL) is a rare form of non-Hodgkin lymphoma affecting the tissues surrounding the eye. It encompasses a spectrum of lymphoid malignancies arising from the eyelids, conjunctiva, lacrimal glands, and orbit. While relatively uncommon, OAL presents unique challenges due to its varied clinical manifestations and diverse histological subtypes. Understanding its pathogenesis and molecular mechanisms is crucial for developing targeted therapies. Recent advances in cancer research have shed light on the genetic alterations and immunological factors underlying OAL, paving the way for innovative treatment strategies such as immunotherapy and targeted molecular therapies. Collaborative efforts between oncologists, pathologists, and researchers are essential for elucidating the complexities of OAL and improving patient outcomes.



Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States
Title : Graphene quantum dots: A new frontier for photodynamic therapy
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil